Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Cognition Therapeutics Inc(CGTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CGTX
09/25/2026: CGTX (2-star) is currently NOT-A-BUY. Pass it for now.
Cognition Therapeutics is a clinical-stage biotechnology company focused on developing small molecule therapies for Alzheimer's and other neurodegenerative diseases. Its primary strength lies in a differentiated approach targeting the Sigma-2 receptor complex to protect synaptic function. The company's main investment story rests on the successful clinical validation of its lead candidate, CT1812. However, the firm faces significant risks, including high clinical failure rates, intense competition from well-capitalized pharmaceutical giants, and a reliance on external financing. This stock is best suited for speculative investors with a high risk tolerance who are prepared to monitor clinical trial readouts and regulatory developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth opportunity tied to clinical trial outcomes rather than earnings growth. |
| Momentum investor | Weak fit | Momentum is highly conditional on specific clinical data readouts rather than traditional trend following. |
| Value investor | Weak fit | The lack of earnings and clinical-stage status makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and requires capital retention for research. |
| Low-risk investor | Weak fit | Biotech clinical-stage stocks involve extreme volatility and high risk of capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can lead to drastic, sudden stock price movements. |
| Valuation risk | High | Valuations are based on speculative long-term clinical success rather than current cash flows. |
| Competition risk (Alzheimer's therapy market) | High | Competing with multi-billion dollar firms with approved products creates significant commercial hurdles. |
| Business quality | Medium | The company has a clear scientific focus but lacks the diversified revenue streams of mature firms. |
| Dividend income | Low / none | Income generation is not part of the business model. |
| Execution risk | High | Failure to successfully execute complex clinical trials would materially damage the company's prospects. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 125.44% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.06M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 406.1K shares | Beta 1.79 | 52 Weeks Range 0.55 - 2.05 | Updated Date 09/26/2026 |
52 Weeks Range 0.55 - 2.05 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and clinical testing of pipeline candidates like CT1812. | The company currently spends money to develop products; it does not yet have products to sell. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 59.89M | Price to Sales(TTM) - |
Enterprise Value 59.89M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.44 | Shares Outstanding 95.09M | Shares Floating 87.42M |
Shares Outstanding 95.09M | Shares Floating 87.42M | ||
Percent Insiders 1.29 | Percent Institutions 23.79 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cognition Therapeutics Inc
Exchange NASDAQ | Headquarters Purchase, NY, United States | ||
IPO Launch date 2021-10-08 | CEO, President & Director Ms. Lisa Ricciardi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.cogrx.com |
Full time employees 14 | Website https://www.cogrx.com | ||
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.